UBE2Q1 in a Human Breast Carcinoma Cell Line: Overexpression and Interaction with p53

Sayed Mohammad Shafiee1&, Mozhgan Rasti1&, Atefeh Seghatoleslam1, Tayebeh Azimi1, Ali Akbar Owji1,2*

Abstract

The p53 tumor suppressor protein is a principal mediator of growth arrest, senescence, and apoptosis in response to a broad array of cellular damage. p53 is a substrate for the ubiquitin-proteasome system, however, the ubiquitin-conjugating enzymes (E2s) involved in p53 ubiquitination have not been well studied. UBE2Q1 is a novel E2 ubiquitin conjugating enzyme gene. Here, we investigated the effect of UBE2Q1 overexpression on the level of p53 in the MDA-MB-468 breast cancer cell line as well as the interaction between UBE2Q1 and p53. By using a lipofection method, the p53 mutated breast cancer cell line, MDA-MB-468, was transfected with the vector pCMV6-AN-GFP, containing UBE2Q1 ORF. Western blot analysis was employed to verify the overexpression of UBE2Q1 in MDA-MB-468 cells and to evaluate the expression level of p53 before and after cell transfection. Immunoprecipitation and GST pull-down protocols were used to investigate the binding of UBE2Q1 to p53. We established MDA-MB-468 cells that transiently expressed a GFP fusion proteins containing UBE2Q1 (GFP-UBE2Q1). Western blot analysis revealed that levels of p53 were markedly lower in UBE2Q1 transfected MDA-MB-468 cells as compared with control MDA-MB-468 cells. Both in vivo and in vitro data showed that UBE2Q1 co-precipitated with p53 protein. Our data for the first time showed that overexpression of UBE2Q1 can lead to the repression of p53 in MDA-MB-468 cells. This repression of p53 may be due to its UBE2Q1 mediated ubiquitination and subsequent proteasome degradation, a process that may involve direct interaction of UBE2Q1 with p53.

Keywords: UPS - UBE2Q1 - breast cancer - p53

Introduction

The ubiquitin-proteasome system (UPS) serves to identify and degrade unwanted intracellular proteins. This system consists of ubiquitin, three ubiquitination enzymes, and the proteasome that degrades the ubiquitin-tagged target proteins. The ubiquitination enzymes, ubiquitin activating enzymes (E1), ubiquitin conjugating enzymes (E2) and ubiquitin ligases (E3), work in concert to link a ubiquitin chain to a specific target protein. Initially ubiquitin is activated by an E1 in an ATP-dependent manner. The E1 transfers the activated ubiquitin to E2s. Ubiquitin loaded E2s selectively interact with E3s that recruit and bind specific substrates (Dahlmann, 2007). In a few cases, however, ubiquitination may proceed without the direct involvement of E3s (Hoeller et al., 2007). As such, UPS acts as a regulator of a variety of protein substrates that play important roles in normal cellular functions and in processes of carcinogenesis including, proliferation, apoptosis, angiogenesis and motility/metastasis (Goldstein et al., 1975). Alterations in ubiquitination has been shown to be associated with destabilization of tumor suppressors (Ohta and Fukuda, 2004; Lee and Gu, 2010) and over expression of oncogenes (Wei et al., 2005; Muller and Eilers, 2008).

Contribution of the components of the UPS, specifically E2s to tumorigenesis has begun to be verified. E2 proteins like UbcH10 (also known as UBE2C) and UBE2S (also named E2-EPF) have shown to be closely linked to the cell cycle progression and hence tumorigenesis. These E2 proteins normally work with the E3 ligase APC/C (Anaphase Promoting Complex/ Cyclosome) in the regulation of cell cycle (Bremm and Komander, 2011; Tang et al., 2014).

Breast cancer is the most common malignancy in women in both developed and developing countries (Voutsadakis, 2013; Karami et al., 2014; Mermer and Turk, 2014). The importance of ubiquitination in breast cancer is highlighted by the fact that several key proteins in breast cancer such as estrogen receptor-α (ERα), progesterone receptor (PR) and transcription factor NF-κB are targets for modifications by ubiquitin and ubiquitin-like proteins. It is also reported that activation of the...
UBE2Q1 overexpression on the level of p53 in MDA-
(Seghatoleslam et al., 2006; Seghatoleslam et al., 2012b).

These enzymes and is differentially expressed in breast tumors. Other hereditary breast cancers may be due to mutations in genes coding for p53 regulator proteins (Lacroix et al., 2006). A significant proportion of these cancers have been associated with mutations of BRCA1 (Hohenstein and Giles, 2003). p53 mediates its own down-regulation by inducing the expression of Mdm2 that is an E3 ubiquitin-protein ligase. Recently, it is reported that Mdm2 cooperates with different E2 enzymes to regulate the stability and function of p53 (Moll and Petenko, 2003). E2 enzymes like UBE2D2 (Ubch15b) and UBE2D3 have also shown to mediate the ubiquitination and down-regulation of p53 (Saville et al., 2004).

Recently we have reported that the novel human gene, UBE2Q1, is a putative member of E2 family of enzymes and is differentially expressed in breast tumors (Seghatoleslam et al., 2012b), colorectal cancer (Shafiee et al., 2013) and pediatric acute lymphoblastic leukemia (Seghatoleslam et al., 2014). UBE2Q1 is very similar to another human protein, UBE2Q2 that has already been shown to be overexpressed in malignancies such as head and neck squamous cell carcinoma (Seghatoleslam et al., 2006), breast cancer (Nikseresht et al., 2010), acute lymphoblastic leukemia (Seghatoleslam et al., 2012a) and colorectal primary tumors (Shafiee et al., 2014).

Overexpression of UBE2Q2 can negatively affect cell proliferation and anchorage-independent cell growth (Maeda et al., 2009; Seghatoleslam and Zambrano, 2009). A ubiquitin conjugate enzyme E2 domain is predicted at the C-terminal of both UBE2Q1 and UBE2Q2 proteins (Seghatoleslam et al., 2006; Seghatoleslam et al., 2012b).

In the present study we investigated the effect of UBE2Q1 overexpression on the level of p53 in MDA-MB-468 line of breast cancer cells and also checked the interaction of UBE2Q1 protein with native and mutant p53 in MCF7 and MDA-MB-468 cells respectively.

Materials and Methods

Cell culture

Breast cancer cell lines MCF7 (p53-positive) and MDA-MB-468 (p53-mutant) were obtained from national cell bank of Iran (Pasteur Institute, Iran). Cell lines were cultured in 10% fetal calf serum (Cinagen, Iran) containing media (Biosera, UK) of RPMI 1640 and maintained under an atmosphere of 5% CO2 in a humid incubator at 37°C.

Cell transfection

Transfections of MDA-MB-468 cells with UBE2Q1 cDNA were performed by the lipofection method using Lipofectamine® 2000 transfection reagent (Invitrogen, USA) according to the manufacturer’s procedure. Human UBE2Q1 ORF cDNA clone (NM_017582.6) in pcMV6-AN-GFP vector was from Origene (USA). The control transfection was performed by pCMV6-AN-GFP vector without UBE2Q1 ORF. Overexpression of UBE2Q1 by these cells was verified by Western blot analysis using anti UBE2Q1 antibody as discussed below.

Protein extraction and Western blot analysis

To extract protein from cultured cells, after detachment of the cells from the flasks using cell scraper, they were lysed in extraction buffer containing 150 mM sodium chloride, 1.0% NP-40 (V/V), 50 mM Tris, pH 8.0 and protease inhibitor cocktail (Roche, Germany). Lysates were sonicated at 4°C for 30 s and then maintained in constant agitation for 30 minutes at 4°C and finally cleared by centrifugation. Protein concentration was measured using Bradford reagent. Electrophoresis (Mini-PROTEAN Tetra Cells BioRad, USA) of 30 µg protein samples were performed on 12.5% discontinuous sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS- PAGE) and the proteins were transferred onto nitrocellulose membrane (PROTRAN Nitrocellulose transfer Membrane, Whatman, USA) at 25 V for 18 h in cold room (Mini Trans-Blot Cell, BioRad, USA). The membranes were blocked for 1 h in 5% dried fat free milk, at room temperature and incubated with specific primary antibodies diluted in blocking solution (1:2,000 for anti UBE2Q1 antibody and 1:500 for anti p53 antibody) at 4°C overnight. The anti UBE2Q1 antibody was a polyclonal rabbit antiserum generated against the peptide ATDRLMKELRDIYRSQSF corresponding to amino acid sequences 252–269 of UBE2Q1 (Seghatoleslam et al., 2012b). Anti-p53 antibody was also generated in our recombinant protein laboratory (Rasti et al., 2012). Blots were washed three times in PBS-Tween (PBS-T) and incubated with specific secondary antibodies coupled to HRP (HRP-conjugated goat anti-rabbit IgG, Abcam, USA) (1:2,500) at a concentration of 1 µg/ml in 2% (W/V) BSA in PBS-T. All samples were also blotted for β-actin (1:1000) to normalize the amounts of protein. A chemiluminescent substrate (Chemiluminescent Kit, BioRad, USA) were used for detecting the bands on
membranes. Light emission was captured by exposing the membrane to X-ray films.

Immunoprecipitation and GST pull-downs

MCF7 and MDA-MB-468 breast cancer cell lines were lysed in a buffer containing 10 mM Tris-HCl pH 7.4, 0.825 M NaCl and 1% (v/v) NP-40. Cell lysates were sonicated and cleared by centrifugation. Five milligrams of the protein lysate was used for immunoprecipitation and GST pull-down studies. Immunocomplexes were precipitated using 5 μl of polyclonal rabbit antiserum against either p53 (Rasti et al., 2012) or UBE2Q1 (Seghatoleslam et al., 2012b). After 2 hours of mixing at 4°C on a rotator, 30 μl of packed protein G agarose beads (Sigma, UK) were added to the protein-antibody complex and mixed for a further 1 hour. Immunocomplexes bound to the beads were then spun and washed, prior to re-suspension in the SDS sample buffer for SDS-PAGE analysis. Western blotting was performed by using antisera against p53 and UBE2Q1. For GST pull-downs, 50 μg of GST-p53 which were made in our lab (Rasti et al., 2012) was mixed with each cell lysate for 2 hours at 4°C. GST fusion protein complexes were eluted from glutathione-agarose columns by 25 mM reduced glutathione in 50 mM Tris-HCl solution pH 8.0. The samples were resolved by SDS-PAGE and then subjected to Western blot analysis with UBE2Q1 antibody.

Results

Effects of UBE2Q1 overexpression on the cellular levels of p53

MDA-MB-468 cells were transfected by pCMV6-AN-GFP vector, containing UBE2Q1 coding sequence and also by the empty pCMV6-AN-GFP vector as a control. Western blot analysis of lysates from GFP-UBE2Q1 transfected MDA-MB-468 cells revealed an intense band of UBE2Q1 immunoreactivity at about 70 KD that is close to the molecular weight (23KD+46.127KD) expected of UBE2Q1. Western blot analysis of lysates from GFP-UBE2Q1 showed the interaction between GST-p53 and UBE2Q1 (Figure 1A). Therefore we established MDA-MB-468 cells that transiently expressed p53 and the mutant p53 in MCF7 and MDA-MB-468 Cells. Lysates from nontransfected (lane 1), empty vector-transfected (lane 2) and GFP-UBE2Q1 transfected MDA-MB-468 cells (lane 3) were Western blotted and probed with antibodies against UBE2Q1 (A) and p53 (B). Anti-β-actin antibody was used to confirm equal loading.

Interaction between p53 and UBE2Q1

We studied the binding of UBE2Q1 to wild type (WT) p53 and the mutant p53 in MCF7 and MDA-MB-468 cells respectively. To verify these interactions, we carried out in vitro and in vivo binding studies. In vivo binding assays were performed by preparing lysates from MDA-MB-468 and MCF7 cells. Lysates from these cells were immunoprecipitated with anti-p53 or with anti-UBE2Q1 antibodies and subjected to Western blotting afterwards. The blots were probed with the reciprocal antisera. Results showed that both WT and mutant p53 are able to co-immunoprecipitate with UBE2Q1. This interaction was not detected when rabbit immunoglobulin G was used as a control for non-specific immunoprecipitation (Figure 2A). For in vitro binding assays GST-p53 was expressed in E. coli and purified with glutathione-agarose beads (Rasti et al., 2012). A pull-down assay was performed by incubating the GST-p53 with lysates from each of the cancer cell lines. Protein complexes were subjected to Western blotting and probed by anti-UBE2Q1 antibody. As shown in Figure 2B, UBE2Q1 was able to coprecipitate with GST-p53 but not with GST.

Discussion

Results of this study imply that UBE2Q1, a novel putative E2 enzyme, interacts with the p53 tumor suppressor protein. The regulation of p53 turnover by the UPS is a key issue in the understanding of molecular basis of tumorigenesis (Yang et al., 2004). Ubiquitination
of proteins, however, signals cellular processes other than proteinolysis that also participate in the development of cancer (Ohta and Fukuda, 2004; Mani and Gelmann, 2005; Dahlmann, 2007). Many proteins implicated in malignancies including breast cancer are involved in the UPS (Ohta and Fukuda, 2004). Central in the UPS are E2s that interact with several E3 ubiquitin ligases (Mani and Gelmann, 2005). Mdm2 is an E3 enzyme which has a central role in degradation of p53 as a tumor suppressor (Devine and Dai, 2012). Thus, exploration of E2 partners of Mdm2 as well as E2s that directly interact with p53 is important, particularly to understand the roles of E2s in p53 turnover and the process of carcinogenesis. Here, we sought to study the possible interaction of UBE2Q1 with wild type (WT) p53 and the mutant p53 in MCF7 and MDA-MB-468 cells respectively.

Data of our study clearly shows that overexpression of the novel E2 enzyme, UBE2Q1, leads to the repression of p53 in MDA-MB-468 cells. This repression of p53 may be due to its UBE2Q1 mediated ubiquitination and subsequent proteasome degradation, a process that may involve direct interaction of UBE2Q1 with p53. Our in vivo co-immunoprecipitation results showed that both WT and mutant p53 expressed respectively in MCF7 and MDA-MB-468 cells co-immunoprecipitated with UBE2Q1.

This finding suggests that UBE2Q1 and p53 can associate into a complex. Results of subsequent GST pull-down experiments implied that co-precipitation of the two proteins may be a result of a direct interaction between them. The fact that p53 gene in MDA-MB-468 cells is mutated at codon 273 (Lacroix et al., 2006) implies that this mutation in p53 does not affect its binding capacity to UBE2Q1. This may be because this mutation affects the DNA binding region (residues 103–292), i.e. the central core region of the protein (Lacroix et al., 2006), whereas the C-terminal lysine residues are suggested to be the main sites of the ubiquitin ligation, that target p53 for proteasome-mediated degradation (Rodriguez et al., 2000). Our previous data also showed that upregulation of UBE2Q1 at the levels of both protein and mRNA is a frequent phenomenon in breast cancer (Seghatoleslam et al., 2012b). Thus, it would be plausible that up-regulation of UBE2Q1 confers a benefit on cancer cells by decreasing the level of p53. This finding is in agreement with the reports in which UBE2Q1 silencing by small interfering RNA caused a significant increase in the levels of p53 and p21 in HepG2 and BEL-7404 cells (Chang et al., 2014) and also the overexpression of UBE2Q1 resulted in decreased cellular level of p53 in PC12 neuronal cells (Wan et al., 2014). It is well established that Mdm2 cooperates with different E2 enzymes for the regulation of p53 stability and function (Lai et al., 2002; Brooks and Gu, 2003). The role of Mdm2, however, in the repression of p53 by UBE2Q1 needs to be confirmed.

To our knowledge this is the first report of binding of UBE2Q1 to p53 protein in vivo and in vitro. p53 might be one of the UBE2Q1 substrates for ubiquitination.

Acknowledgements

This study has been supported by Grant Number 92-6729 from Vice-chancellor for Research Affairs of Shiraz University of Medical Sciences, Shiraz, Iran.

References

UBE2Q1 in a Human Breast Carcinoma Cell Line: Overexpression and Interaction with p53

Pathol Oncol Res, 18, 169-75.


